delavirdine has been researched along with lamivudine in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (26.09) | 18.2507 |
2000's | 9 (39.13) | 29.6817 |
2010's | 7 (30.43) | 24.3611 |
2020's | 1 (4.35) | 2.80 |
Authors | Studies |
---|---|
Haefeli, WE; Ketabi-Kiyanvash, N; Lindenmaier, H; Theile, D; Weiss, J | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
Chen, FE; Chen, WX; De Clercq, E; He, QQ; Pannecouque, C; Piao, HR; Wu, HQ; Wu, Y; Yan, ZH | 1 |
Balzarini, J; Chen, F; Chen, W; De Clercq, E; Liu, Y; Meng, G; Pannecouque, C; Zheng, A | 1 |
Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Chen, W; Daelemans, D; De Clercq, E; Huang, B; Liu, X; Pannecouque, C; Yang, J; Zhan, P | 1 |
Daelemans, D; De Clercq, E; Ding, X; Fang, Z; Huang, B; Kang, D; Li, Z; Liu, X; Lu, X; Pannecouque, C; Xu, H; Zhan, P; Zhang, H; Zhou, Z | 1 |
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Balzarini, J; De Clercq, E; Kleim, JP; Pelemans, H; Riess, G; Roesner, M; Winkler, I | 1 |
Bellman, PC | 1 |
Saag, MS; Schooley, RT | 1 |
Temesgen, Z; Wright, AJ | 1 |
Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
Acosta, EP; Bassett, RL; Bell, D; Eron, JJ; Fife, K; Johnson, VA; Kuritzkes, DR; Marschner, IC; Martinez, A; Murphy, RL; Pettinelli, CB; Sommadossi, JP; Wood, K | 1 |
Adachi, A; Fujiwara, T; Hayami, M; Isaka, Y; Kawauchi, S; Miki, S; Sato, A; Sugimoto, H; Suyama, A; Yoshie, O | 1 |
Anderson, S | 1 |
Ambrose, Z; Herman, BD; Moore, KL; Nissley, DV; Sheen, CW; Sluis-Cremer, N; Tachedjian, G; Zelina, S | 1 |
4 review(s) available for delavirdine and lamivudine
Article | Year |
---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
2 trial(s) available for delavirdine and lamivudine
Article | Year |
---|---|
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delavirdine; Female; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Viral Load; Zidovudine | 2000 |
Delavirdine combination and viral load.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1997 |
17 other study(ies) available for delavirdine and lamivudine
Article | Year |
---|---|
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Cell Line; Dogs; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Inhibitors | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Benzamides; Cell Survival; Cells, Cultured; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication | 2014 |
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2014 |
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
Topics: Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; Molecular Docking Simulation; Protein Conformation; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Water | 2016 |
Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
Topics: Animals; Anti-HIV Agents; Cell Line, Tumor; Drug Resistance, Viral; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Molecular Docking Simulation; Mutation; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfonamides; Thiophenes | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined
Topics: Anti-HIV Agents; Antiviral Agents; Benzodiazepines; Cell Line; Delavirdine; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Quinoxalines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine | 1998 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |
Isolation and characterization of simian immunodeficiency virus variants that are resistant to nonnucleoside reverse transcriptase inhibitors.
Topics: Amino Acid Sequence; Amino Acid Substitution; Delavirdine; Drug Resistance, Microbial; HeLa Cells; Humans; Lamivudine; Molecular Sequence Data; Point Mutation; Reverse Transcriptase Inhibitors; Sequence Alignment; Simian Immunodeficiency Virus; Structure-Activity Relationship | 2000 |
The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
Topics: Adenine; Anti-HIV Agents; Delavirdine; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Lamivudine; Microbial Sensitivity Tests; Mutation, Missense; Nevirapine; Organophosphonates; Protein Binding; Reverse Transcriptase Inhibitors; Tenofovir | 2009 |